Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US03843E1047
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00L9HP0Z0
AQST
Aquestive Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Drug Manufacturers - Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Aquestive Therapeutics Inc
ISIN
US03843E1047
TICKER
AQST
MIC
XNAS
REUTERS
AQST.OQ
BLOOMBERG
AQST US
Thu, 02.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates incl...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, April 1, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) between June 16, 2025 and January 8, 2026,...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 27.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 26, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) between June 16, 2025 and January 8, 2026,...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire b...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Aquestive Therapeutics
US03843E1047

Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA? NEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) risk disclosures during the period from June 16, 2025 through January 8, 2026. Shareholders who lost money on AQST stock may find out if you...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, March 25, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Aquestive Therapeutics
US03843E1047

Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is named as an individual defendant in a pending securities class action. Class Period: June 16, 2025 through January 8, 2026. Find out if you qualify to recover losses or con...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 24.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Aquestive Therapeutics
US03843E1047

SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring imp...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Offi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 19, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) between June 16, 2025 and January 8, 2026,...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, March 19, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, March 18, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 20...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Aquestive Therapeutics
US03843E1047

On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who purchased AQST securities between June 16, 2025 and January 8, 2026 lost over 37% of their investment...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 15.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 14.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 12, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, March 12, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - March 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.03.2026       Aquestive Therapeutics
US03843E1047

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026. Aquestive describes itself as a “pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink